
From: [REDACTED]
Sent: Friday, March 26, 2004 3:32 AM
To: [REDACTED]
Subject: FW: Pooled psychosis abstract for submission CINP
Importance: High

[REDACTED]

-----Original Message-----

From: [REDACTED]
Sent: donderdag 25 maart 2004 18:35
To: [REDACTED]
Subject: RE: Pooled psychosis abstract for submission CINP

At this point, so long after RIS 232 has been completed, I think it is wrong

to continue to submit abstracts of the three pooled studies. At this point, we must be concerned that this gives the strong appearance that Janssen is purposely withholding the findings from RIS 232.

Adverse effect findings from 232 are available on the web through the British government's regulatory site. It was also mentioned by someone from FDA at the AAGP annual meeting. It is not a secret that a fourth study has been conducted. As an investigator who is loyal to this program, I really do have

to speak out and urge that Janssen avoids embarrassment and accusations about suppressing information that is relevant to providers and consumers.

Please forward these concerns to the other coinvestigators and to the company. I think the time has come when pooled analyses should include 232.

[REDACTED]